Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study
- 1 August 1992
- journal article
- clinical trial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 67 (8) , 732-738
- https://doi.org/10.1016/s0025-6196(12)60797-6
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Review article: 5‐hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implicationsAlimentary Pharmacology & Therapeutics, 1992
- Epidemiology of colonic symptoms and the irritable bowel syndromeGastroenterology, 1991
- Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5‐hydroxytryptamine receptor (type 3) antagonistAlimentary Pharmacology & Therapeutics, 1990
- Controlled treatment trials in the irritable bowel syndrome: A critiqueGastroenterology, 1988
- Neuronal 5-HT receptors in the peripheryNeuropharmacology, 1984
- Evaluation of colonic myoelectrical activity in health and functional disorders.Gut, 1980
- Comparison of rectosigmoid myoelectrical activity in the irritable colon syndrome during relapses and remissions.Gut, 1978
- What the Gastroenterologist Does All DayGastroenterology, 1976
- Intestinal Motility in ManGastroenterology, 1966
- OBSERVATIONS CONCERNING THE ACTION OF 5‐HYDROXYTRYPTAMINE ON THE PERISTALTIC REFLEXBritish Journal of Pharmacology and Chemotherapy, 1958